Grifols S.A. ADR Aktie
Finanztrends
Deine Einschätzung
Was spricht für und gegen Grifols S.A. ADR in den nächsten Jahren?
Pro
?
L*********** I********** f** d** n******* J****
?
A****************
?
W******* i* V********
Kontra
?
U****************
?
M****
?
M************
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Grifols S.A. ADR im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Grifols S.A. ADR | - | -5,63 % | 8,06 % | -25,97 % | -11,84 % | -28,34 % | -46,94 % |
| Beximco Pharmaceuticals Ltd. GDR | 0,00 % | -2,83 % | 11,96 % | 10,52 % | 14,96 % | 28,11 % | -44,62 % |
| Eledon Pharmaceuticals Inc. | -2,03 % | 2,84 % | -14,20 % | -2,03 % | 126,56 % | 150,00 % | -46,30 % |
| SELLAS Life Sciences Group Inc | 0,99 % | 19,82 % | -12,24 % | 664,71 % | 266,84 % | 640,74 % | 39,04 % |
Kommentare
News
Rigel Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Rigel Pharmaceuticals, Inc.? Here are five stocks we like better.
- Strong Q2 performance: Rigel reported $78.7 million in revenue and $17.3 million in net income, with
Grifols Q2 Earnings Call Highlights
Key Points
- Interested in Grifols, S.A.? Here are five stocks we like better.
- Grifols remains on track for its 2026 targets: First-half revenue rose 2.6% to €3.574 billion at constant currency